Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Bases de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Physiol Rev ; 92(1): 1-38, 2012 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-22298650

RESUMO

The anterior pituitary gland has the ability to respond to complex signals derived from central and peripheral systems. Perception of these signals and their integration are mediated by cell interactions and cross-talk of multiple signaling transduction pathways and transcriptional regulatory networks that cooperate for hormone secretion, cell plasticity, and ultimately specific pituitary responses that are essential for an appropriate physiological response. We discuss the physiopathological and molecular mechanisms related to this integrative regulatory system of the anterior pituitary gland and how it contributes to modulate the gland functions and impacts on body homeostasis.


Assuntos
Comunicação Celular/fisiologia , Hipófise/citologia , Hipófise/fisiologia , Transdução de Sinais/fisiologia , Animais , Sistema Endócrino/fisiologia , Homeostase/fisiologia , Hormônios/metabolismo , Humanos , Sistemas Neurossecretores/fisiologia
2.
Neuroendocrinology ; 94(2): 124-36, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21525729

RESUMO

SOM230 (pasireotide) is a multiligand somatostatin (SRIF) analog able to bind to somatostatin receptor (SSTR) subtypes 1, 2, 3 and 5, and trigger antisecretory and antiproliferative signaling cascades. Canines have become in vivo models to test the pharmacological treatment of corticotropinomas because they frequently develop Cushing's disease in a spontaneous manner, due to adrenocorticotropic hormone (ACTH)-producing pituitary adenomas. Different levels of expression of SSTR2 and SSTR5 have been shown in both mouse AtT20 cells and canine tumoral corticotropinoma cells. The objective of this study was to evaluate whether SOM230 controls both tumor cell growth and hormone synthesis, therefore controlling the disease. SOM230 was tested in dogs suffering from Cushing's disease (10 animals were treated continuously during 6 months, and another 10 were treated with 3 cycles consisting of 2 months of treatment followed by a 2-month rest period). A significant decrease in ACTH, urinary cortisol creatinine ratio, adenoma size (magnetic nuclear resonance) and improvement of clinical signs were obtained, without side effects. AtT20 cells treated with SOM230 suppressed pro-opiomelanocortin (POMC) promoter activity through SSTR2, via the G(i) α-subunit, and reduced Nur77/Nurr1 transcriptional activity. We conclude that SOM230, in addition to its well-described antisecretory effects, inhibits, as shown in AtT20 cells, ACTH synthesis at the POMC transcriptional level, an effect mediated mainly through SSTR2, and limits tumor growth. The controlled Cushing's disease in the dogs that received the treatment indicates that SOM230 has a potential therapeutic use in humans suffering from Cushing's disease.


Assuntos
Hormônio Adrenocorticotrópico/biossíntese , Corticotrofos/efeitos dos fármacos , Corticotrofos/metabolismo , Hipersecreção Hipofisária de ACTH/metabolismo , Somatostatina/análogos & derivados , Hormônio Adrenocorticotrópico/sangue , Alanina Transaminase/sangue , Fosfatase Alcalina/sangue , Animais , Aspartato Aminotransferases/sangue , Glicemia/metabolismo , Linhagem Celular Tumoral , Colesterol/sangue , Creatinina/urina , Cães , Feminino , Hidrocortisona/urina , Testes de Função Hepática , Imageamento por Ressonância Magnética , Masculino , Hipersecreção Hipofisária de ACTH/patologia , Somatostatina/farmacologia , Triglicerídeos/sangue , alfa-MSH/sangue
3.
Horm Res ; 72(5): 266-74, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19844112

RESUMO

Research performed on the pituitary has proven that cytokines play an important role in maintaining pituitary physiology, affecting not only cell proliferation but also hormone secretion. The effects of cytokines can be autocrine or paracrine. This review gives an overview on the effects of the most studied cytokines in the pituitary. Special interest is focused on interleukin-6 (IL-6) because it has the distinctive characteristic of stimulating pituitary tumor cell growth, but has the opposite effect on normal pituitary cells. On the other hand, IL-6 is a cytokine of interest in the pituitary because recent work has shown that it promotes and maintains senescence in certain types of tumors. Given that the majority of pituitary adenomas are microadenomas and the fact that clinically inapparent pituitary tumors are quite common, senescence, perhaps mediated by IL-6, is an attractive mechanism for explaining the benign nature of pituitary tumors.


Assuntos
Citocinas/fisiologia , Hipófise/fisiologia , Adenoma/etiologia , Animais , Senescência Celular/fisiologia , Citocinas/metabolismo , Humanos , Interleucina-6/fisiologia , Modelos Biológicos , Hipófise/crescimento & desenvolvimento , Hipófise/metabolismo , Hipófise/patologia , Neoplasias Hipofisárias/etiologia
4.
Oncotarget ; 8(3): 4690-4702, 2017 Jan 17.
Artigo em Inglês | MEDLINE | ID: mdl-27902467

RESUMO

Cellular senescence is a stable proliferative arrest state. Pituitary adenomas are frequent and mostly benign, but the mechanism for this remains unknown. IL-6 is involved in pituitary tumor progression and is produced by the tumoral cells. In a cell autonomous fashion, IL-6 participates in oncogene-induced senescence in transduced human melanocytes. Here we prove that autocrine IL-6 participates in pituitary tumor senescence. Endogenous IL-6 inhibition in somatotroph MtT/S shRNA stable clones results in decreased SA-ß-gal activity and p16INK4a but increased pRb, proliferation and invasion. Nude mice injected with IL-6 silenced clones develop tumors contrary to MtT/S wild type that do not, demonstrating that clones that escape senescence are capable of becoming tumorigenic. When endogenous IL-6 is silenced, cell cultures derived from positive SA-ß-gal human tumor samples decrease the expression of the senescence marker. Our results establish that IL-6 contributes to maintain senescence by its autocrine action, providing a natural model of IL-6 mediated benign adenoma senescence.


Assuntos
Comunicação Autócrina , Interleucina-6/genética , Interleucina-6/metabolismo , Neoplasias Hipofisárias/metabolismo , Animais , Linhagem Celular Tumoral , Proliferação de Células , Senescência Celular , Inibidor p16 de Quinase Dependente de Ciclina/metabolismo , Humanos , Camundongos , Camundongos Nus , Invasividade Neoplásica , Transplante de Neoplasias , Fosforilação , Neoplasias Hipofisárias/genética , Neoplasias Hipofisárias/patologia , Proteína do Retinoblastoma/metabolismo , beta-Galactosidase/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA